ValiRx plc (AIM:VAL)

Market Cap	1.50M -23.8%
Revenue (ttm)	49.78K +418.5%
Net Income	-1.78M
EPS	-0.01
Shares Out	767.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,162,243
Open	0.1954
Previous Close	0.1950
Day's Range	0.1900 - 0.2000
52-Week Range	0.1800 - 0.8750
Beta	-0.56
Analysts	n/a
Price Target	n/a
Earnings Date	May 5, 2026

About ValiRx

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 14
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VAL

Financial Performance

In 2024, ValiRx's revenue was 49,775, an increase of 418.49% compared to the previous year's 9,600. Losses were -1.92 million, -5.99% less than in 2023.